Wells Fargo Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $38
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target from $45 to $38.
Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target from $45 to $38.